Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma

被引:8
|
作者
Minematsu, Tsuyoshi [1 ]
Felder, Laurie [2 ]
Oppeneer, Todd [2 ]
Sakazume, Masashi [3 ]
Oikawa, Keishi [4 ]
Hashimoto, Tadashi [1 ]
Usui, Takashi [1 ]
Kamimura, Hidetaka [1 ]
机构
[1] Astellas Pharma Inc, Drug Metab Res Labs, Itabashi Ku, Tokyo 1748511, Japan
[2] Covance Labs Inc, Madison, WI USA
[3] Astellas Res Technol Co Ltd, Tokyo, Japan
[4] Astellas Pharma Inc, Clin Pharmacol, Tokyo, Japan
关键词
YM155; bioanalytical method; LC-MS/MS; validation; pharmacokinetics; dog plasma;
D O I
10.1002/bmc.996
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This paper describes a sensitive and selective liquid chromatography with tandem mass spectrometry (LC-MS/MS) method for determination of the novel survivin suppressant YM155, 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium, which is developed for the treatment of solid tumors. This method uses a liquid-liquid extraction from 0.25 mL of dog plasma. LC separation was carried out on a Genesis Silica column (50 mm x 3.0 mm i.d.) at a flow-rate of 0.5 mL/min. Compounds were eluted using a mobile phase of 5 mm ammonium acetate and 0.1% formic acid in water-0.1% formic acid in acetonitrile, 17:83 (v/v). MS/MS detection was carried out with an MDS-Sciex API3000 triple quadrupole mass spectrometer in positive electrospray ionization mode. The standard curve was linear from 0.05 to 50 ng/mL (r >= 0.9968). The lower limit of quantitation was 0.05 ng/mL. Good intra- and inter-day assay precision (within 7.4% RSD) and accuracy (within +/- 12.3%) were obtained. The extraction recovery was 66.2%. The method was successfully applied to preelinical pharmacokinetic studies in dogs. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:763 / 769
页数:7
相关论文
共 50 条
  • [1] Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of halofuginone in plasma
    Parise, RA
    Sparrow, BR
    Merrill, JW
    Grossi, IM
    Covey, JM
    Peggins, JO
    Egorin, MJ
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 810 (01): : 35 - 40
  • [2] Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma
    Dolman, M. Emmy M.
    den Hartog, Ilona J. M.
    Molenaar, Jan J.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    Sparidans, Rolf W.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2014, 92 : 144 - 148
  • [3] Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant
    Kawano, Hiroki
    Shakushiro, Kohsuke
    Nakata, Mari
    Kita, Aya
    Maeda, Atsushi
    Watanabe, Shunsuke
    Sako, Kazuhiro
    Oku, Naoto
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 88 (01) : 283 - 289
  • [4] YM155, a Novel Small-Molecule Survivin Suppressant, Combined With Radiation Therapy in Prostate Cancer Cell Lines
    Thoms, J.
    Aoki, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S648 - S648
  • [5] Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS
    Minoda, Masaya
    Kawamoto, Teruya
    Ueha, Takeshi
    Kamata, Etsuko
    Morishita, Masayuki
    Harada, Risa
    Toda, Mitsunori
    Onishi, Yasuo
    Hara, Hitomi
    Kurosaka, Masahiro
    Akisue, Toshihiro
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (03) : 891 - 899
  • [6] Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non-Small Cell Lung Cancer Cell Lines
    Iwasa, Tsutomu
    Okamoto, Isamu
    Suzuki, Minoru
    Nakahara, Takahito
    Yamanaka, Kentaro
    Hatashita, Erina
    Yamada, Yuki
    Fukuoka, Masahiro
    Ono, Koji
    Nakagawa, Kazuhiko
    CLINICAL CANCER RESEARCH, 2008, 14 (20) : 6496 - 6504
  • [7] Pharmacokinetics, distribution and excretion of YM155 monobromide, a novel small-molecule survivin suppressant, in male and pregnant or lactating female rats
    Minematsu, Tsuyoshi
    Sonoda, Takuya
    Hashimoto, Tadashi
    Iwai, Megumi
    Oppeneer, Todd
    Felder, Laurie
    Shirai, Nobuaki
    Miyashita, Aiji
    Usui, Takashi
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2012, 33 (03) : 160 - 169
  • [8] YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts
    Nakahara, Takahito
    Takeuchi, Masahiro
    Kinoyama, Isao
    Minematsu, Tsuyoshi
    Shirasuna, Kenna
    Matsuhisa, Akira
    Kita, Aya
    Tominaga, Fumiko
    Yamanaka, Kentaro
    Kudoh, Masafumi
    Sasamata, Masao
    CANCER RESEARCH, 2007, 67 (17) : 8014 - 8021
  • [9] Formulation Design and Evaluation of Liposomal Sepantronium Bromide (YM155), a Small-Molecule Survivin Suppressant, Based on Pharmacokinetic Modeling and Simulation
    Kohsuke Shakushiro
    Hiroki Kawano
    Mari Nakata
    Aya Kita
    Atsushi Maeda
    Shunsuke Watanabe
    Kazuhiro Sako
    Naoto Oku
    Pharmaceutical Research, 2015, 32 : 238 - 247
  • [10] Formulation Design and Evaluation of Liposomal Sepantronium Bromide (YM155), a Small-Molecule Survivin Suppressant, Based on Pharmacokinetic Modeling and Simulation
    Shakushiro, Kohsuke
    Kawano, Hiroki
    Nakata, Mari
    Kita, Aya
    Maeda, Atsushi
    Watanabe, Shunsuke
    Sako, Kazuhiro
    Oku, Naoto
    PHARMACEUTICAL RESEARCH, 2015, 32 (01) : 238 - 247